Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Melanoma 3Colorectal Neoplasms 2Thyroid Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1EGFR-mutant Non-small Cell Lung Cancer 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 141Nivolumab 117Ipilimumab 69Cyclophosphamide 34Specimen Handling 30Magnetic Resonance Spectroscopy 28trametinib 23fludarabine 22binimetinib 22Interleukin-2 21dabrafenib 19relatlimab 17encorafenib 17Biopsy 17aldesleukin 16CTLA-4 Antigen 16fludarabine phosphate 15cemiplimab 15atezolizumab 15Radiosurgery 15Opdualag 14Radiotherapy 11lifileucel 10lenvatinib 10Blood Specimen Collection 10spartalizumab 8Paclitaxel 8Cisplatin 8Bevacizumab 8cobimetinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × naporafenib × 1 year × Clear all
NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Novartis

Phase 2 Active not recruiting
134 enrolled
Dermatologic

Melanoma

NCT05907304 2026-02-27

SEACRAFT-1

Erasca, Inc.

Phase 1 Active not recruiting
86 enrolled
DermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT06346067 2026-02-27

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Erasca, Inc.

Phase 3 Active not recruiting
78 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡